SecSonar.com

Xilio Therapeutics, Inc. (XLO)

Xilio Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Xilio Therapeutics, Inc. (XLO) is a Biotechnology company based in US with a market capitalization of $49.8M. Free cash flow was negative at -$5.5M. This page tracks XLO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 64 employees · IPO Oct 22, 2021

Valuation

Valuation & price

$8.36 · as of May 17, 2026 · -30.8% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.41

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$11.80$9.48$7.16Jul 25Dec 25Jul 26Jul 7, 25$9.79Jul 9, 25$10.28Jul 11, 25$10.28Jul 15, 25$9.98Jul 17, 25$10.15Jul 21, 25$9.77Jul 23, 25$9.65Jul 25, 25$9.75Jul 29, 25$9.80Jul 31, 25$9.08Aug 4, 25$9.20Aug 6, 25$9.24Aug 11, 25$9.52Aug 13, 25$10.01Aug 15, 25$9.93Aug 19, 25$9.54Aug 21, 25$9.38Aug 25, 25$9.80Aug 27, 25$9.58Aug 29, 25$9.80Sep 3, 25$10.13Sep 5, 25$9.80Sep 9, 25$10.50Sep 11, 25$10.22Sep 16, 25$10.72Sep 18, 25$10.69Sep 22, 25$10.71Sep 24, 25$10.72Sep 26, 25$11.14Sep 30, 25$11.80Oct 2, 25$11.20Oct 6, 25$11.54Oct 8, 25$11.77Oct 10, 25$11.12Oct 14, 25$10.63Oct 16, 25$10.61Oct 21, 25$10.58Oct 23, 25$10.82Oct 27, 25$11.63Oct 29, 25$11.34Oct 31, 25$11.15Nov 4, 25$11.23Nov 6, 25$11.64Nov 10, 25$11.27Nov 12, 25$10.83Nov 14, 25$9.90Nov 18, 25$10.50Nov 20, 25$10.50Nov 25, 25$10.57Nov 28, 25$10.61Dec 2, 25$9.89Dec 4, 25$10.37Dec 8, 25$10.22Dec 10, 25$10.05Dec 12, 25$9.54Dec 16, 25$9.10Dec 18, 25$9.10Dec 22, 25$9.27Dec 24, 25$9.31Dec 29, 25$9.10Jan 2, 26$9.40Jan 6, 26$9.73Jan 8, 26$10.13Jan 12, 26$9.33Jan 14, 26$9.04Jan 16, 26$8.96Jan 21, 26$8.36Jan 23, 26$8.80Jan 27, 26$8.61Jan 29, 26$8.54Feb 2, 26$8.23Feb 4, 26$7.65Feb 9, 26$7.64Feb 11, 26$7.49Feb 13, 26$8.12Feb 18, 26$7.99Feb 20, 26$7.95Feb 24, 26$7.65Feb 26, 26$7.51Mar 2, 26$7.57Mar 4, 26$7.62Mar 6, 26$7.42Mar 10, 26$7.84Mar 12, 26$7.16Mar 17, 26$7.43Mar 19, 26$7.29Mar 23, 26$7.86Mar 25, 26$8.53Mar 27, 26$8.32Mar 31, 26$8.41Apr 2, 26$8.51Apr 7, 26$8.50Apr 9, 26$8.56Apr 13, 26$8.46Apr 15, 26$8.40Apr 17, 26$8.57Apr 22, 26$8.60Apr 24, 26$8.31Apr 28, 26$7.92Apr 30, 26$7.92May 4, 26$8.33May 6, 26$7.90May 8, 26$7.74May 12, 26$7.73May 14, 26$8.81May 18, 26$8.15May 20, 26$8.44May 22, 26$8.25May 28, 26$8.52Jun 1, 26$8.25Jun 3, 26$8.15Jun 5, 26$7.70Jun 9, 26$7.90Jun 11, 26$7.99Jun 15, 26$8.34Jun 17, 26$8.75Jun 22, 26$8.94Jun 24, 26$9.01Jun 26, 26$9.05Jul 2, 26$9.15
$7.1452-week range$12.08
Loading valuation history…

Fundamentals

Key fundamentals

$49.8M

Market cap

—

Revenue growth (YoY)

96.5%

Gross margin

-$5.5M

Free cash flow (USD)

-$130.6M

Net debt

Net cash position

2087.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$0.00FY 2024$6.3MFY 2025$43.8M
$0$43.8M

Free cash flow by year

2019 → 2025

FY 2019$-18.6MFY 2020$-38.3MFY 2021$-81.9MFY 2022$-77.6MFY 2023$-69.1MFY 2024$-18.4MFY 2025$-5.5M
-$18.6M-$5.5M

Gross margin by year

2024 → 2025

FY 2024100.0%FY 202596.5%
100.0%96.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventDirector AppointmentJun 12, 2026Filing
  • FinancingSecurities RegistrationMay 27, 2026Filing
  • 8-K eventEarnings ReleaseMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • FinancingSecurities RegistrationMay 12, 2026Filing
  • 8-K eventDirector AppointmentApr 16, 2026Filing

Questions

Frequently asked questions

What is Xilio Therapeutics, Inc.'s market cap?

Xilio Therapeutics, Inc. (XLO) has a market capitalization of $49.8M.

What is XLO's P/E ratio?

A meaningful P/E ratio is not available for XLO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is XLO's price-to-book (P/B) ratio?

XLO trades at 1.41 times book value per share.

Are insiders buying XLO stock?

SEC Form 4 filings show no open-market insider buys at Xilio Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

ELUT

Elutia Inc.

$49.7M

GOSS

Gossamer Bio, Inc.

$49.4M

MGX

Metagenomi, Inc. Common Stock

$51.6M

ATYR

aTyr Pharma, Inc.

$53.9M

MREO

Mereo BioPharma Group plc

$55.5M

CUE

Cue Biopharma, Inc.

$57.5M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.